CN110770236B - Vmat2抑制剂化合物及其组合物 - Google Patents

Vmat2抑制剂化合物及其组合物 Download PDF

Info

Publication number
CN110770236B
CN110770236B CN201880040884.XA CN201880040884A CN110770236B CN 110770236 B CN110770236 B CN 110770236B CN 201880040884 A CN201880040884 A CN 201880040884A CN 110770236 B CN110770236 B CN 110770236B
Authority
CN
China
Prior art keywords
compound
methyl
group
pharmaceutically acceptable
piperazino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880040884.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN110770236A (zh
Inventor
尼科尔·哈里奥特
唐纳德·赫廷格
肖恩·布拉努姆
杰弗里·C·卡尔亨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62111264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110770236(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CN110770236A publication Critical patent/CN110770236A/zh
Application granted granted Critical
Publication of CN110770236B publication Critical patent/CN110770236B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201880040884.XA 2017-04-19 2018-04-17 Vmat2抑制剂化合物及其组合物 Active CN110770236B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762487413P 2017-04-19 2017-04-19
US62/487,413 2017-04-19
US201862652837P 2018-04-04 2018-04-04
US62/652,837 2018-04-04
PCT/US2018/028031 WO2018195121A1 (en) 2017-04-19 2018-04-17 Vmat2 inhibitor compounds and compositions thereof

Publications (2)

Publication Number Publication Date
CN110770236A CN110770236A (zh) 2020-02-07
CN110770236B true CN110770236B (zh) 2023-03-24

Family

ID=62111264

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880040884.XA Active CN110770236B (zh) 2017-04-19 2018-04-17 Vmat2抑制剂化合物及其组合物

Country Status (17)

Country Link
US (1) US11040970B2 (enExample)
EP (1) EP3612532B1 (enExample)
JP (1) JP7170662B2 (enExample)
KR (1) KR20190140968A (enExample)
CN (1) CN110770236B (enExample)
AU (1) AU2018254429A1 (enExample)
BR (1) BR112019021853A2 (enExample)
CA (1) CA3060251A1 (enExample)
CL (1) CL2019002919A1 (enExample)
CO (1) CO2019011604A2 (enExample)
ES (1) ES2971230T3 (enExample)
JO (1) JOP20190239A1 (enExample)
MA (1) MA50145A (enExample)
MX (1) MX2019012336A (enExample)
PE (1) PE20191784A1 (enExample)
TW (1) TW201841913A (enExample)
WO (1) WO2018195121A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230170136A (ko) 2017-01-27 2023-12-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
JOP20200298A1 (ar) * 2018-06-14 2020-11-22 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات وطرق تتعلق بها
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2020086765A1 (en) * 2018-10-24 2020-04-30 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
JP7559059B2 (ja) 2019-09-30 2024-10-01 インサイト・コーポレイション 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物
EP4058461A1 (en) 2019-11-11 2022-09-21 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
PE20240822A1 (es) 2021-03-22 2024-04-18 Neurocrine Biosciences Inc Inhibidores de vmat2 y metodos de uso
WO2022232380A1 (en) 2021-04-29 2022-11-03 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
CA3229341A1 (en) 2021-08-20 2023-02-23 Ryan TERRY-LORENZO Methods of screening for vmat2 inhibitors
WO2026050236A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553487A (zh) * 2006-11-08 2009-10-07 纽罗克里生物科学有限公司 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法
WO2016127133A1 (en) * 2015-02-06 2016-08-11 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
ATE437876T1 (de) 2003-06-20 2009-08-15 Hoffmann La Roche Hexahydropyridoisochinoline als dpp-iv- inhibitoren
JP2008509925A (ja) * 2004-08-13 2008-04-03 オメロス コーポレイション 新規のセロトニンレセプターリガンドおよびそれらの使用
FR2912145B1 (fr) 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US9012471B2 (en) * 2008-04-11 2015-04-21 The Trustees Of Columbia University In The City Of New York Glucose metabolism modulating compounds
NZ591615A (en) 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2784830C (en) * 2009-12-18 2018-03-27 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
WO2014043866A1 (zh) 2012-09-19 2014-03-27 中国科学院福建物质结构研究所 噻吩[2,3-d]嘧啶衍生物、其制备方法及其用途
US9782398B2 (en) 2014-02-07 2017-10-10 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
EP4223369A1 (en) 2016-12-22 2023-08-09 Incyte Corporation Immunomodulator compounds and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553487A (zh) * 2006-11-08 2009-10-07 纽罗克里生物科学有限公司 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法
WO2016127133A1 (en) * 2015-02-06 2016-08-11 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthesis of Bioactive 2-Aza-Analogues of Ipecac and Alangium Alkaloids;Koelzer, Michael;《ChemMedChem》;20101231;第5卷(第9期);1456-1464页 *

Also Published As

Publication number Publication date
JP7170662B2 (ja) 2022-11-14
US11040970B2 (en) 2021-06-22
MX2019012336A (es) 2020-07-14
PE20191784A1 (es) 2019-12-24
KR20190140968A (ko) 2019-12-20
AU2018254429A1 (en) 2019-11-07
EP3612532B1 (en) 2023-12-13
EP3612532A1 (en) 2020-02-26
MA50145A (fr) 2020-07-29
CL2019002919A1 (es) 2020-01-17
EP3612532C0 (en) 2023-12-13
WO2018195121A1 (en) 2018-10-25
BR112019021853A2 (pt) 2020-05-26
TW201841913A (zh) 2018-12-01
CO2019011604A2 (es) 2019-10-31
CN110770236A (zh) 2020-02-07
CA3060251A1 (en) 2018-10-25
JP2020517607A (ja) 2020-06-18
JOP20190239A1 (ar) 2019-10-09
US20200131173A1 (en) 2020-04-30
ES2971230T3 (es) 2024-06-04

Similar Documents

Publication Publication Date Title
JP7170662B2 (ja) Ｖｍａｔ２インヒビター化合物およびその組成物
JP7155206B2 (ja) 神経学的疾患または障害を処置するためのｖｍａｔ２阻害剤
JP7107950B2 (ja) 特定のｖｍａｔ２インヒビターを投与するための方法
JP2024114905A (ja) Ｖｍａｔ２インヒビター化合物、上記化合物に関する組成物および方法
JP2025071099A (ja) 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
HK40049687A (en) Vmat2 inhibitor compounds, compositions, and methods relating thereto
HK40098364A (en) Methods of administering certain vmat2 inhibitors
BR112017027839B1 (pt) Uso de inibidores de vmat2 para preparação de uma composição farmacêutica para tratar mania em um transtorno de humor em um indivíduo; e/ou tratar transtorno obsessivo-compulsivo (toc) refratário ao tratamento

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant